A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2019-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared
with placebo in participants with moderate-to-severe atopic dermatitis.